Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone SR and Fluoxetine in OCD
NCT00758966Phase 2Terminated
- Sponsor
- Orexigen Therapeutics
- Start
- Sep 2008
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of naltrexone in obsessive compulsive disorder (OCD) (3 arms), sponsored by Orexigen Therapeutics. Primary endpoint: Yale-Brown Obsessive Compulsive Scale at 10 weeks. Started Sep 2008; status: terminated.
02
Drugs
naltrexone
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT00758966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00758966.